COEGIN — Coegin Pharma AB Income Statement
0.000.00%
Last trade - 00:00- SEK180.11m
- SEK167.78m
Annual income statement for Coegin Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | Interim Report | ARS | ARS | ARS |
| Standards: | SAS | — | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 46.3 | 27.2 | 34.7 | 27.8 | 23.3 |
| Operating Profit | -46.3 | -27.2 | -34.7 | -27.8 | -23.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -46.2 | -27.1 | -35.2 | -28 | -23.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -46.2 | -27.1 | -35.2 | -28 | -23.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -46.2 | -27.1 | -35.2 | -28 | -23.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -46.2 | -27.1 | -35.2 | -28 | -23.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -29.4 | -3.83 | -4.43 | -2.7 | -1.26 |
| Dividends per Share |